Effects of fatty acid bile acid conjugates (FABACs) on biliary lithogenesis: potential consequences for non-surgical treatment of gallstones.
Fatty acid bile acid conjugates (FABACs) are novel synthetic lipid molecules, which were designed for the treatment of cholesterol gallstones. The rationale was to combine a cholesterol solubilizing moiety (a saturated fatty acid) with a bile acid (cholic acid) as a vehicle to enable secretion into bile and entry into the enterohepatic circulation. An amide bond was used to provide stability against intestinal degradation. Initial in vitro studies showed that FABACs are indeed cholesterol solubilizers, able to prevent biliary cholesterol crystallization. Arachidyl-amido-cholanoic acid (Aramchol) was found to be the most potent FABAC in these studies. Animal studies revealed that Aramchol was absorbed after oral administration and could prevent cholesterol crystallization as well as dissolve preformed crystals in rodents fed a lithogenic diet. In gallstone susceptible mice, Aramchol prevented gallstone formation and dissolved gallstones. FABACs were found to be metabolically active substances, also able to decrease blood cholesterol, atherosclerotic plaques and fat accumulation in the liver in several animal species. The underlying mechanisms of action are under active investigation, and several effects, e.g. on cholesterol and bile salt metabolizing enzymes as well as cholesterol efflux from cells have been discovered. These findings are, however, only the beginning of our understanding of the metabolic actions as well as the potential of use of FABACs as therapeutic agents.
Konikoff
Fred M
FM
Minerva Center for Cholesterol Gallstones and Lipid Metabolism in the Liver, Sackler Faculty of Medicine, Tel Aviv University, Israel. konikoff@post.tau.ac.il
Gilat
Tuvia
T
D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control; D001646:Bile / Q000187:drug effects; D001647:Bile Acids and Salts / Q000627:therapeutic use*; D002784:Cholesterol / Q000378:metabolism; D005227:Fatty Acids / Q000627:therapeutic use*; D005234:Fatty Liver / Q000378:metabolism; D042882:Gallstones / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans
D001647:Bile Acids and Salts; D005227:Fatty Acids; D002784:Cholesterol